ADA and Vogt-Koyanagi-Harada disease: Our findings demonstrate that TNF-α inhibition with ADA, often administered alongside conventional IMT, effectively controls inflammation and reduces corticosteroid dependence in patients with chronic recurrent VKH disease refractory to conventional treatments.